福坦替尼治疗温抗体型自身免疫性溶血性贫血:3期、随机、双盲、安慰剂对照全球研究(FORWARD)
这项3期随机双盲安慰剂对照全球研究纳入90例对至少一种既往治疗反应不足的温抗体型自身免疫性溶血性贫血患者,福坦替尼组与安慰剂组各45例。主要终点持久血红蛋白应答率分别为35.6%与26.7%(p=.398),差异未达统计学显著。事后分析显示北美、澳大利亚和西欧患者中福坦替尼组持久应答率显著高于安慰剂组(36% vs 10.7%,p=.030)。
要点
- 福坦替尼组持久血红蛋白应答率35.6%,安慰剂组26.7%,差异未达统计学显著(p=.398)。
- 北美、澳大利亚和西欧患者中福坦替尼组持久应答率36%,安慰剂组10.7%(p=.030)。
- 福坦替尼组最常见不良事件为腹泻(26.7%)、高血压(24.4%)和疲乏(15.6%)。
核心结论
- 福坦替尼在西方地区患者中显示出有临床意义的获益,未发现新的安全性信号。
研究设计与样本
- 3期随机双盲安慰剂对照全球研究,纳入对至少一种既往温抗体型自身免疫性溶血性贫血治疗反应不足的患者。
- 共随机90例患者,福坦替尼组45例,安慰剂组45例,治疗期24周。
主要发现
- 福坦替尼组35.6%患者达到持久血红蛋白应答,安慰剂组26.7%(p=.398)。
- 北美、澳大利亚和西欧患者中福坦替尼组持久血红蛋白应答率36%,安慰剂组10.7%(p=.030)。
- 对筛查期间接受类固醇救援所影响的血红蛋白值进行删失并排除2例可能非温抗体型自身免疫性溶血性贫血的安慰剂患者后,再分析显示福坦替尼组15/45(33.3%)vs 安慰剂组6/43(14.0%)达到持久血红蛋白应答(p=.0395)。
- 福坦替尼组至少1例不良事件发生率93.3%(42例),安慰剂组88.9%(40例);福坦替尼组最常见不良事件为腹泻26.7%、高血压24.4%、疲乏15.6%。
关键数值与推荐
- 持久血红蛋白应答定义为治疗24周期间连续3次访视血红蛋白≥10 g/dL且较基线升高≥2 g/dL。
临床怎么用
- 原文未据此给出推荐。
局限性
- 事后分析发现东欧患者中存在较大的安慰剂反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Warm antibody autoimmune hemolytic anemia (wAIHA) is characterized by hemolysis and symptomatic anemia with no approved treatment options. Fostamatinib is an oral spleen tyrosine kinase inhibitor approved in the US and Europe for treatment of adults with chronic immune thrombocytopenia. In this phase 3 study, patients with an insufficient response to ≥1 prior wAIHA treatment were randomized to fostamatinib or placebo. The primary endpoint was the proportion of patients to achieve a durable hemoglobin (Hgb) response (Hgb ≥10 g/dL and increase from baseline of ≥2 g/dL on 3 consecutive visits) during the 24-week treatment period. Ninety patients were randomized, 45 to each arm. Of the fostamatinib-treated patients, 35.6% achieved a durable Hgb response versus 26.7% on placebo (p = .398). A post hoc analysis revealed a large placebo response in Eastern European patients. Significantly more patients on fostamatinib from North America, Australia and Western Europe exhibited a durable Hgb response compared to placebo (36% vs. 10.7%, p = .030). After censoring for Hgb values impacted by steroid rescue received during screening and excluding 2 placebo patients found to likely not have wAIHA, a reanalysis demonstrated a difference in durable Hgb response between fostamatinib and placebo (15/45 [33.3%] vs. 6/43 [14.0%], p = .0395). At least 1 AE was reported in 42 (93.3%) and 40 (88.9%) patients receiving fostamatinib and placebo, respectively. The most common AEs in the fostamatinib group were diarrhea (26.7%), hypertension (24.4%), and fatigue (15.6%). In this study, fostamatinib demonstrated a clinically meaningful benefit for patients in Western regions, and no new safety signals were identified.
引用
- Kuter DJ, Piatek C, Röth A, et al. Fostamatinib for warm antibody autoimmune hemolytic anemia: Phase 3, randomized, double-blind, placebo-controlled, global study (FORWARD). Am J Hematol. 2023. PMID: 37929318. doi:10.1002/ajh.27144
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。